Details of the Drug

General Information of Drug (ID: DMBSI6Y)

Drug Name
KITE-718
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Drug Type
TCR-T cell therapy
Cross-matching ID
TTD ID
DN46RL

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Melanoma-associated antigen 3 (MAGEA3) TTWSKHD MAGA3_HUMAN Not Available [2]
Melanoma-associated antigen 6 (MAGEA6) TTJIWMO MAGA6_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT03139370) Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers. U.S. National Institutes of Health.